Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.37 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20320548 | 0.78 | CNR2 (0.38) | CNR2CNR1MBOAT4KDM4EALDH1A1 | |
| SCHEMBL23966685 | 0.77 | MEN1 (0.41) | CNR2CNR1 | |
| SCHEMBL25799445 | 0.76 | CNR2 (0.39) | CNR2CNR1ALDH1A1 | |
| SCHEMBL1012674 | 0.74 | BRD4 (0.33) | KDM4EALDH1A1MAPTBLM | |
| SCHEMBL1012946 | 0.74 | ALDH1A1 (0.33) | KDM4EALDH1A1MAPTBLM | |
| SCHEMBL17796648 | 0.74 | CYP1A2 (0.38) | CNR2CNR1KDM4EALDH1A1MAPT | |
| SCHEMBL25796919 | 0.72 | CNR2 (0.36) | CNR2CNR1 | |
| SCHEMBL29010902 | 0.71 | CNR2 (0.39) | CNR2CNR1ALDH1A1 | |
| SCHEMBL9713142 | 0.71 | KDM4E (0.31) | CNR2KDM4EALDH1A1MAPTBLM | |
| SCHEMBL24410810 | 0.71 | KDM4E (0.31) | KDM4EALDH1A1MAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12344601-B2 | (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-07-01 | — | — | US | disclosed |
| US-20240092769-A1 | (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-03-21 | — | — | US | disclosed |
| US-11725004-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-11725004-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-11725004-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-8865744-B1 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-20140121206-A1 | TRPV4 ANTAGONISTS | GlaxoSmithKliine, LLC (US) | 2014-05-01 | — | — | US | disclosed |
| EP-2721016-A1 | TRPV4 ANTAGONISTS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-04-23 | — | — | EP | disclosed |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| US-8618289-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-12-31 | — | — | US | disclosed |
| WO-2013012500-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2011-05-19 | — | — | US | disclosed |
| CN-102026985-A | Quinazoline derivatives as RAF kinase modulators and methods and uses thereof | AMBIT BIOSCIENCES CORPORATON | 2011-04-20 | — | — | CN | disclosed |
| EP-2268623-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121206-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV3, TRPV5 | CNR2 272/4885CNR1 239/4885MBOAT4 3652/4885 |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | CNR2 3219/4885CNR1 2528/4885MBOAT4 3647/4885 |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | CNR2 3192/4885CNR1 2317/4885MBOAT4 4484/4885 |
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | CNR2 3084/4885CNR1 2194/4885MBOAT4 4515/4885 |
| US-11725004-B2 | (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885MBOAT4 1343/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | CNR2 4544/4885CNR1 4436/4885MBOAT4 4041/4885 |
| US-20240092769-A1 | (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885MBOAT4 1343/4885 |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | CNR2 2910/4885CNR1 2814/4885MBOAT4 4581/4885 |
| US-12344601-B2 | (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885MBOAT4 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.